English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Purpose: To evaluate intravitreal Bevacizumab (IVB) in treatment of diabetic macular edema (DME) using Multifocal Electroretinogram (Mf-ERG). Methods: Twenty eyes of sixteen patients with diffuse and/or focal DME without macular ischemia received primary IVB (1.25 mg /0.1 ml). Multifocal electroretinography was done as baseline, 1 week, 2 weeks and 3 weeks post injection. Results: Mean visual acuity improved from (0.37±0.23) to (0.42±0.30), 25% of patients reported near vision improvement. Central foveal thickness improved significantly from (375.80±14.48 micrometer (μm)) to (225.0±30.08 μm) and parafoveal and perifoveal thickness improved from (317.00±36.2 μm) to (282.80±27.97 μm). At the end of the 3 week, P wave amplitude improved from (34.64±9.62 nanovolt per square degree (nV/deg2)) to (44.54±8.32 nV/deg2), N wave amplitude improved from (0.135±0.060 nV/deg2) to (0.299±0.160 nV/deg2). Conclusion: Intravitreal Bevacizumab resulted in macular function improvement in the study patients with DME, postoperative improvement in visual acuity and decreased retinal thickness confirmed by improvement of P wave and N wave

Assessment of Macular Function by Multifocal Electroretinogram after Intravitreal Injection of Bevacizumab in Diabetic Macular Edema